Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-0159 (Barzolvolimab) in healthy subjects
NCT04146129Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) comparing CDX-0159 with Placebo (2 arms). Primary endpoint: Safety as assessed by CTCAE v5.0. Started Oct 2019; status: completed.
02
Drugs
barzolvolimab
03
Conditions
chronic spontaneous urticaria (CSU)chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT04146129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146129.